Versantis
Latest round
- Series B
Last raised
- Sep 2019
Total raised
- $21M
Investors
- 9
About Versantis
Founded in 2015, Versantis AG operates out of Zurich, Switzerland, concentrating on the development of therapies for acute-on-chronic liver failure (ACLF). The company was acquired by Genfit in September 2022 for CHF 40 million, with contingent consideration based on future clinical successes. The acquisition aims to strengthen Genfit's position in the liver disease market.Versantis AG is primarily dedicated to developing pharmaceutical products targeting rare and life-threatening liver diseases. Their key offerings include innovative therapeutic solutions for Acute-on-Chronic Liver Failure (ACLF) and chronic liver conditions like Primary Biliary Cholangitis (PBC). The company’s pipeline consists of five assets, each utilizing distinct mechanisms to tackle specific liver disease challenges, alongside a diagnostic portfolio focused on Metabolic dysfunction-associated steatohepatitis (MASH) and ammonia-related conditions.Versantis AG generates its revenue through strategic partnerships and collaborations with pharmaceutical companies, such as Ipsen, which oversees regulatory applications and commercialization of its products. Their revenue model is built on milestone payments and royalties linked to the progression of drugs through clinical stages.Following the recent acquisition by Genfit, Versantis AG is positioned for future growth through the continuous development of its clinical assets. The company’s strategy includes the advancement of therapies VS-01 and VS-02, with a focus on achieving positive Phase 2 results and obtaining regulatory approval for VS-01. The acquisition, valued at CHF 40 million, is expected to close in Q4 2022 and is intended to elevate Genfit's leadership in the treatment of ACLF. Versantis plans to leverage this backing to expand its market presence, particularly in Europe and North America, aligning its developmental goals with Genfit's strategic vision.
Who invested in Versantis
9 investors across 3 rounds
See all investors in Versantis
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Versantis
Who invested in Versantis?
Versantis has 9 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Versantis raised?
Versantis has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Versantis last raise money?
Versantis's most recent round on record is a Series B, in Sep 2019.
What does Versantis do?
Founded in 2015, Versantis AG operates out of Zurich, Switzerland, concentrating on the development of therapies for acute-on-chronic liver failure (ACLF).
Where is Versantis headquartered?
Versantis is headquartered in Zurich, Switzerland.
Which VCs invest in companies like Versantis?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back pharmaceuticals companies at Versantis's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Versantis? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.